Cantor Fitzgerald Weighs in on Valeant Pharmaceuticals International, Inc.’s FY2018 Earnings (TSE:VRX)

Valeant Pharmaceuticals International, Inc. (TSE:VRX) (NYSE:VRX) – Equities research analysts at Cantor Fitzgerald lowered their FY2018 earnings per share (EPS) estimates for shares of Valeant Pharmaceuticals International in a research note issued to investors on Monday, Zacks Investment Research reports. Cantor Fitzgerald analyst L. Chen now anticipates that the specialty pharmaceutical company will post earnings per share of $3.77 for the year, down from their prior forecast of $4.44.

A number of other equities analysts have also recently commented on VRX. Royal Bank of Canada reissued a “sector perform” rating and issued a C$23.00 price target on shares of Valeant Pharmaceuticals International in a research note on Wednesday, November 8th. TD Securities upgraded shares of Valeant Pharmaceuticals International from a “hold” rating to a “buy” rating and set a C$25.50 price objective for the company in a report on Wednesday, November 8th.

Valeant Pharmaceuticals International (VRX) traded down C$0.08 during mid-day trading on Thursday, reaching C$29.73. 1,550,000 shares of the company’s stock were exchanged, compared to its average volume of 2,870,000. Valeant Pharmaceuticals International has a fifty-two week low of C$11.20 and a fifty-two week high of C$30.56. The stock has a market cap of $10,350.00, a PE ratio of 6.08 and a beta of -0.67.

In other Valeant Pharmaceuticals International news, Director Schutter Richard Urbain De acquired 10,000 shares of the stock in a transaction dated Friday, November 17th. The stock was purchased at an average cost of C$14.33 per share, for a total transaction of C$143,300.00.

COPYRIGHT VIOLATION WARNING: This piece was first posted by Week Herald and is the sole property of of Week Herald. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://weekherald.com/2018/01/14/valeant-pharmaceuticals-international-inc-to-post-fy2018-earnings-of-3-77-per-share-cantor-fitzgerald-forecasts-vrx.html.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Get a free copy of the Zacks research report on Valeant Pharmaceuticals International (VRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Valeant Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply